12 Sep 2016 07:00
12 September 2016
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Final Results
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2016 on Wednesday, 12 October 2016.
Please further information, please visit www.diurnal.co.uk or contact:
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Ian Ardill, CFO | |
Numis Securities Ltd | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam | |
Corporate Broking: James Black | |
FTI Consulting | + 44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
DNL.L (DNL)